search
Back to results

Analysis of the Results of Intense Pulsed Light Treatment Previously to Laser Refractive Surgery

Primary Purpose

Meibomian Gland Dysfunction, Blepharitis

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Study group
Control group
Sponsored by
Vissum, Instituto Oftalmológico de Alicante
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Meibomian Gland Dysfunction focused on measuring Intense pulsed light, LASIK / SMILE

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients over 18 years of age who are undergoing a corneal laser refractive surgery after a medical indication by the Vissum ophthalmologist

Exclusion Criteria:

  • Pregnancy
  • Piercings
  • Fitzpatrick skin classification V and VI
  • Autoimmune diseases
  • Epilepsy
  • Previous history of herpes or ocular pathology
  • Pathological or suspicious corneal topography
  • Treatment in the previous month with corticosteroids, antihistamines or topical vasoconstrictors.

Sites / Locations

  • Alicante Vissum MiranzaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Study group

Control group

Arm Description

IPL + laser refractive surgery

Laser refractive surgery without IPL

Outcomes

Primary Outcome Measures

OSDI questionnaire
It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology.
Change from Baseline OSDI questionnaire
It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology.
Change from Baseline OSDI questionnaire
It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology.
Change from Baseline OSDI questionnaire
It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology.
Change from Baseline OSDI questionnaire
It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology.
Lacrimal meniscus height
Measured in millimeters by Ocular Keratograph 5M, a value greater than 0.20 mm is considered normal
Change from Baseline Lacrimal meniscus height
Measured in millimeters, a value greater than 0.20 mm is considered normal
Change from Baseline Lacrimal meniscus height
Measured in millimeters, a value greater than 0.20 mm is considered normal
Change from Baseline Lacrimal meniscus height
Measured in millimeters, a value greater than 0.20 mm is considered normal
Change from Baseline Lacrimal meniscus height
Measured in millimeters, a value greater than 0.20 mm is considered normal
Tear Break-up-time
Time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal.
Change from Baseline Tear Break-up-time
time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal.
Change from Baseline Tear Break-up-time
time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal.
Change from Baseline Tear Break-up-time
time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal.
Change from Baseline Tear Break-up-time
time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal.
Conjunctival and ciliary hyperemia.
Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe)
Change from Baseline Conjunctival and ciliary hyperemia.
Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe)
Change from Baseline Conjunctival and ciliary hyperemia.
Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe)
Change from Baseline Conjunctival and ciliary hyperemia.
Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe)
Change from Baseline Conjunctival and ciliary hyperemia.
Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe)
Upper and lower meibography
Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification Grade 0: no loss of meibomian glands. Grade 1: loss of less than 1/3 of the total surface of the meibomian glands. Grade 2: loss of 1/3 to 2/3 of the total area. Grade 3: loss of more than 2/3 of the surface.
Change from Baseline Upper and lower meibography
Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification Grade 0: no loss of meibomian glands. Grade 1: loss of less than 1/3 of the total surface of the meibomian glands. Grade 2: loss of 1/3 to 2/3 of the total area. Grade 3: loss of more than 2/3 of the surface.
Change from Baseline Upper and lower meibography
Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification Grade 0: no loss of meibomian glands. Grade 1: loss of less than 1/3 of the total surface of the meibomian glands. Grade 2: loss of 1/3 to 2/3 of the total area. Grade 3: loss of more than 2/3 of the surface.
Change from Baseline Upper and lower meibography
Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification Grade 0: no loss of meibomian glands. Grade 1: loss of less than 1/3 of the total surface of the meibomian glands. Grade 2: loss of 1/3 to 2/3 of the total area. Grade 3: loss of more than 2/3 of the surface.
Change from Baseline Upper and lower meibography
Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification Grade 0: no loss of meibomian glands. Grade 1: loss of less than 1/3 of the total surface of the meibomian glands. Grade 2: loss of 1/3 to 2/3 of the total area. Grade 3: loss of more than 2/3 of the surface.

Secondary Outcome Measures

Visual acuity
Visual acuity with and without correction, measured on a decimal scale, determined by the Snellen panel, placing the examined person at a distance of 6 meters, will be collected by an optician.
Change from Baseline Visual acuity
Visual acuity with and without correction, measured on a decimal scale, determined by the Snellen panel, placing the examined person at a distance of 6 meters, will be collected by an optician.
Corneal topography
Performs an analysis of the cornea, which allows evaluating the shape and quantifying the power of the different curvatures
Change from Baseline Corneal topography
Performs an analysis of the cornea, which allows evaluating the shape and quantifying the power of the different curvatures
Corneal aberrometry
Technique that analyzes complex systems of light waves to quantify the set of optical aberrations that exist within the ocular structure.
Change from Baseline Corneal aberrometry
Technique that analyzes complex systems of light waves to quantify the set of optical aberrations that exist within the ocular structure.
Analysis of contrast sensitivity
Contrast Sensitivity is a test that assesses a person's ability to identify an object and separate it from the background Contrast sensitivity is evaluated with charts that can be used as projected or wall acuity charts.
Change from Baseline Analysis of contrast sensitivity
Contrast Sensitivity is a test that assesses a person's ability to identify an object and separate it from the background Contrast sensitivity is evaluated with charts that can be used as projected or wall acuity charts.
VAS questionnaire
investigates the intensity of the ocular surface symptoms from 0 to 100 (normal- severe)
Change from Baseline VAS questionnaire
investigates the intensity of the ocular surface symptoms from 0 to 100 (normal- severe)

Full Information

First Posted
November 4, 2021
Last Updated
October 17, 2022
Sponsor
Vissum, Instituto Oftalmológico de Alicante
search

1. Study Identification

Unique Protocol Identification Number
NCT05139511
Brief Title
Analysis of the Results of Intense Pulsed Light Treatment Previously to Laser Refractive Surgery
Official Title
Analysis of the Efficacy and Safety of Intense Pulsed Light Treatment for the Ocular Surface in Patients Who Will Undergo Laser Refractive Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
February 15, 2021 (Actual)
Primary Completion Date
April 15, 2023 (Anticipated)
Study Completion Date
August 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vissum, Instituto Oftalmológico de Alicante

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Dry eye is often reported as the most common complication after a laser refractive surgery. Any refractive procedure can lead an impact on the corneal surface and the tear film. The main cause of this dry eye is the corneal denervation caused by the destruction of the anterior stromal nerves during the ablative procedure. This loss of corneal sensitivity leads to a decrease in the blink reflex, a decrease in the secretion rate of the meibomian glands and finally an evaporated dry eye. There is also a chronic inflammation at the corneal surface that produces an increase of inflammatory cytokines and a dysfunction of the meibomian glands. Yu et al have described incidences of dry eye closed to 60% after the first month of LASIK. Hovanesian et al have observed dry eye symptoms in 50% of patients 6 months after surgery. Donnenfeld et al describe 15% of moderate dry eye in the following 3 months and 5% of severe dry eye in the first 6 months. A small number of patients will present with chronic dry eye symptoms for more than 1 year. Bower et al analyzed its incidence in 0.8% Alterations in the tear film also decrease the quality of the retinal image and produce greater number of high-order due to the irregular. Pulsed light therapy (IPL) applied preoperatively in patients who undergo a laser refractive surgery may prevent the post-surgical dry eye and improve the refractive results. The aim of our study is to evaluate the usefulness of the applied therapy for the prevention of dry eye in patients that undergo a corneal refractive procedure.
Detailed Description
Design Clinical experimental controlled trial, double-blind in which participants will be randomized into 2 groups: a study group (IPL + laser refractive surgery) and a control group (laser refractive surgery without IPL). The study will be conducted in accordance with Law 14/2007 of 3 July, on Biomedical Research, the Declaration of Helsinki (October 2013 version), standards of Good Clinical Practice and legislation in this area. All participants included in the study should read the Information Sheet and sign the informed and voluntary consent. Participants Participants from Vissum Clinic that present the inclusion criteria and none of the exclusion criteria. The investigators will start the study with a preliminary project and depending on the results obtained, the investigators will apply these values to calculate the final sample size using the T-student-Fischer test for unilateral hypotheses and for a type 1 or α error of 5%. and a type 2 or β error of 20%. Parameters evaluated Primary measures: age, sex, skin phototype, visual acuity with and without correction, refraction, cycloplegic refraction, OSDI and VAS questionnaire, use of artificial tears, oxford scale, lacrimal meniscus height, tear break-up time, conjunctival hyperemia, meibography and slit lamp examination. Secondary measures: corneal topography and tomography (MS-39, CSO, Italy), corneal aberrometry (MS-39, CSO, Italy), ocular aberrometry (Osiris, CSO, Italy), analysis of contrast sensitivity (CSV-1000, Vector vision), photographic capture of the epithelial defect in PRK, pre-surgical and postsurgical photographic capture of the eyelid changes in PRK. The measurement of the different objective variables will be carried out in the clinic. The measurement of the subjective variables will be carried out by two ophthalmologists, both masked. Surgery and follow-up Participants who are candidates for a LASIK or SMILE procedure will receive, after randomization, IPL treatment in both eyes (experimental group) or sham IPL (control group). In the case of participant candidate for a PRK procedure, an intra-subject control group will be used, where one eye will receive the IPL treatment (right eyes) and the left contralateral eye the sham IPL treatment (control). Refractive surgeries will be performed exclusively two ophthalmologists following the same surgical protocol. IPL therapy (M22, Lumenis LTD, Israel) will be performed following the same protocol (standardized facial and periocular application with automatically adjusted energy according to Fitzpatrick skin classification). Three IPL sessions will be applied (simulated in the case of the control group): 7 days before the intervention, 7 days after the intervention, and 30 days after the intervention. The total postsurgical follow-up will be 6 months. Statistical analyses All demographic and clinical data will be collected in a database and analyzed with the SPSS statistical package for Windows version 22.0. A p <0.05% will be considered significant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Meibomian Gland Dysfunction, Blepharitis
Keywords
Intense pulsed light, LASIK / SMILE

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Clinical experimental controlled trial, double-blind in which participants will be randomized into 2 groups: a study group and a control group
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Study group
Arm Type
Experimental
Arm Description
IPL + laser refractive surgery
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Laser refractive surgery without IPL
Intervention Type
Device
Intervention Name(s)
Study group
Other Intervention Name(s)
Intense pulsed light therapy (Lumenis M22)
Intervention Description
The IPL therapy consists in a polychromatic pulses of light not coherent and not collimated. The therapy leads to a series of processes such as the destruction of superficial blood vessels and thus the reduction of local inflammation, the liquefy of the meibum and an antimicrobial, anti-inflammatory and antioxidant effects. The therapy is performed over the cheeks, nose and upper eyelids.
Intervention Type
Other
Intervention Name(s)
Control group
Intervention Description
Same procedure but without energy
Primary Outcome Measure Information:
Title
OSDI questionnaire
Description
It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology.
Time Frame
0 day
Title
Change from Baseline OSDI questionnaire
Description
It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology.
Time Frame
7 day
Title
Change from Baseline OSDI questionnaire
Description
It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology.
Time Frame
30 day
Title
Change from Baseline OSDI questionnaire
Description
It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology.
Time Frame
90 day
Title
Change from Baseline OSDI questionnaire
Description
It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology.
Time Frame
180 day
Title
Lacrimal meniscus height
Description
Measured in millimeters by Ocular Keratograph 5M, a value greater than 0.20 mm is considered normal
Time Frame
0 day
Title
Change from Baseline Lacrimal meniscus height
Description
Measured in millimeters, a value greater than 0.20 mm is considered normal
Time Frame
7 day
Title
Change from Baseline Lacrimal meniscus height
Description
Measured in millimeters, a value greater than 0.20 mm is considered normal
Time Frame
30 day
Title
Change from Baseline Lacrimal meniscus height
Description
Measured in millimeters, a value greater than 0.20 mm is considered normal
Time Frame
90 day
Title
Change from Baseline Lacrimal meniscus height
Description
Measured in millimeters, a value greater than 0.20 mm is considered normal
Time Frame
180 day
Title
Tear Break-up-time
Description
Time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal.
Time Frame
0 day
Title
Change from Baseline Tear Break-up-time
Description
time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal.
Time Frame
7 day
Title
Change from Baseline Tear Break-up-time
Description
time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal.
Time Frame
30 day
Title
Change from Baseline Tear Break-up-time
Description
time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal.
Time Frame
90 day
Title
Change from Baseline Tear Break-up-time
Description
time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal.
Time Frame
180 day
Title
Conjunctival and ciliary hyperemia.
Description
Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe)
Time Frame
0 day
Title
Change from Baseline Conjunctival and ciliary hyperemia.
Description
Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe)
Time Frame
7 day
Title
Change from Baseline Conjunctival and ciliary hyperemia.
Description
Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe)
Time Frame
30 day
Title
Change from Baseline Conjunctival and ciliary hyperemia.
Description
Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe)
Time Frame
90 day
Title
Change from Baseline Conjunctival and ciliary hyperemia.
Description
Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe)
Time Frame
180 day
Title
Upper and lower meibography
Description
Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification Grade 0: no loss of meibomian glands. Grade 1: loss of less than 1/3 of the total surface of the meibomian glands. Grade 2: loss of 1/3 to 2/3 of the total area. Grade 3: loss of more than 2/3 of the surface.
Time Frame
0 day
Title
Change from Baseline Upper and lower meibography
Description
Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification Grade 0: no loss of meibomian glands. Grade 1: loss of less than 1/3 of the total surface of the meibomian glands. Grade 2: loss of 1/3 to 2/3 of the total area. Grade 3: loss of more than 2/3 of the surface.
Time Frame
7 day
Title
Change from Baseline Upper and lower meibography
Description
Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification Grade 0: no loss of meibomian glands. Grade 1: loss of less than 1/3 of the total surface of the meibomian glands. Grade 2: loss of 1/3 to 2/3 of the total area. Grade 3: loss of more than 2/3 of the surface.
Time Frame
30 day
Title
Change from Baseline Upper and lower meibography
Description
Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification Grade 0: no loss of meibomian glands. Grade 1: loss of less than 1/3 of the total surface of the meibomian glands. Grade 2: loss of 1/3 to 2/3 of the total area. Grade 3: loss of more than 2/3 of the surface.
Time Frame
90 day
Title
Change from Baseline Upper and lower meibography
Description
Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification Grade 0: no loss of meibomian glands. Grade 1: loss of less than 1/3 of the total surface of the meibomian glands. Grade 2: loss of 1/3 to 2/3 of the total area. Grade 3: loss of more than 2/3 of the surface.
Time Frame
180 day
Secondary Outcome Measure Information:
Title
Visual acuity
Description
Visual acuity with and without correction, measured on a decimal scale, determined by the Snellen panel, placing the examined person at a distance of 6 meters, will be collected by an optician.
Time Frame
0 day
Title
Change from Baseline Visual acuity
Description
Visual acuity with and without correction, measured on a decimal scale, determined by the Snellen panel, placing the examined person at a distance of 6 meters, will be collected by an optician.
Time Frame
180 day
Title
Corneal topography
Description
Performs an analysis of the cornea, which allows evaluating the shape and quantifying the power of the different curvatures
Time Frame
0 day
Title
Change from Baseline Corneal topography
Description
Performs an analysis of the cornea, which allows evaluating the shape and quantifying the power of the different curvatures
Time Frame
180 day
Title
Corneal aberrometry
Description
Technique that analyzes complex systems of light waves to quantify the set of optical aberrations that exist within the ocular structure.
Time Frame
0 day
Title
Change from Baseline Corneal aberrometry
Description
Technique that analyzes complex systems of light waves to quantify the set of optical aberrations that exist within the ocular structure.
Time Frame
180 day
Title
Analysis of contrast sensitivity
Description
Contrast Sensitivity is a test that assesses a person's ability to identify an object and separate it from the background Contrast sensitivity is evaluated with charts that can be used as projected or wall acuity charts.
Time Frame
0 day
Title
Change from Baseline Analysis of contrast sensitivity
Description
Contrast Sensitivity is a test that assesses a person's ability to identify an object and separate it from the background Contrast sensitivity is evaluated with charts that can be used as projected or wall acuity charts.
Time Frame
180 day
Title
VAS questionnaire
Description
investigates the intensity of the ocular surface symptoms from 0 to 100 (normal- severe)
Time Frame
0 day
Title
Change from Baseline VAS questionnaire
Description
investigates the intensity of the ocular surface symptoms from 0 to 100 (normal- severe)
Time Frame
180 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients over 18 years of age who are undergoing a corneal laser refractive surgery after a medical indication by the Vissum ophthalmologist Exclusion Criteria: Pregnancy Piercings Fitzpatrick skin classification V and VI Autoimmune diseases Epilepsy Previous history of herpes or ocular pathology Pathological or suspicious corneal topography Treatment in the previous month with corticosteroids, antihistamines or topical vasoconstrictors.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jorge Alió del Barrio, MD, PhD
Phone
965154062
Ext
+34
Email
jorge_alio@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Alejandra Rodriguez, MSc, PhD
Phone
965154062
Ext
+34
Email
clinicaltrials@vissum.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jorge Alió del Barrio, MD, PhD
Organizational Affiliation
Vissum Miranza
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Maria Martinez Hergueta, MD
Organizational Affiliation
Universidad Miguel Hernández
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Maria A Amesty, MD, PhD
Organizational Affiliation
Vissum Miranza
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Mario Cantó Cerdan, MSc
Organizational Affiliation
Vissum Miranza
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Alejandra Rodriguez, MSc, PhD
Organizational Affiliation
Vissum Miranza
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jorge L Alió y Sanz, MD, PhD
Organizational Affiliation
Vissum Miranza
Official's Role
Study Chair
Facility Information:
Facility Name
Alicante Vissum Miranza
City
Alicante
ZIP/Postal Code
03016
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alejandra E Rodriguez, MSc, PhD
Phone
965154062
Ext
+34
Email
clinicaltrials@vissum.com

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Data will be anonymized by assigning a code file and only authorized personnel will have access to personally identifiable data. The highest levels of professional conduct and confidentiality will always be maintained, complying with Organic Law 3/2018, of December 5, on the Protection of Personal Data and guarantee of digital rights.
Citations:
PubMed Identifier
17216074
Citation
Solomon R, Donnenfeld ED, Perry HD. The effects of LASIK on the ocular surface. Ocul Surf. 2004 Jan;2(1):34-44. doi: 10.1016/s1542-0124(12)70022-8.
Results Reference
result
PubMed Identifier
30481814
Citation
Toda I. Dry Eye After LASIK. Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES109-DES115. doi: 10.1167/iovs.17-23538.
Results Reference
result
PubMed Identifier
32188437
Citation
Ge J, Liu N, Wang X, Du Y, Wang C, Li Z, Li J, Wang L. Evaluation of the efficacy of optimal pulsed technology treatment in patients with cataract and Meibomian gland dysfunction in the perioperative period. BMC Ophthalmol. 2020 Mar 18;20(1):111. doi: 10.1186/s12886-020-01357-5.
Results Reference
result
PubMed Identifier
26989003
Citation
Jung JW, Han SJ, Nam SM, Kim TI, Kim EK, Seo KY. Meibomian gland dysfunction and tear cytokines after cataract surgery according to preoperative meibomian gland status. Clin Exp Ophthalmol. 2016 Sep;44(7):555-562. doi: 10.1111/ceo.12744. Epub 2016 May 1.
Results Reference
result
PubMed Identifier
11097583
Citation
Yu EY, Leung A, Rao S, Lam DS. Effect of laser in situ keratomileusis on tear stability. Ophthalmology. 2000 Dec;107(12):2131-5. doi: 10.1016/s0161-6420(00)00388-2.
Results Reference
result
PubMed Identifier
11311627
Citation
Hovanesian JA, Shah SS, Maloney RK. Symptoms of dry eye and recurrent erosion syndrome after refractive surgery. J Cataract Refract Surg. 2001 Apr;27(4):577-84. doi: 10.1016/s0886-3350(00)00835-x.
Results Reference
result
PubMed Identifier
20712970
Citation
Nettune GR, Pflugfelder SC. Post-LASIK tear dysfunction and dysesthesia. Ocul Surf. 2010 Jul;8(3):135-45. doi: 10.1016/s1542-0124(12)70224-0.
Results Reference
result
PubMed Identifier
32182637
Citation
Cote S, Zhang AC, Ahmadzai V, Maleken A, Li C, Oppedisano J, Nair K, Busija L, Downie LE. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020 Mar 18;3(3):CD013559. doi: 10.1002/14651858.CD013559.
Results Reference
result
PubMed Identifier
29688838
Citation
Rong B, Tang Y, Tu P, Liu R, Qiao J, Song W, Toyos R, Yan X. Intense Pulsed Light Applied Directly on Eyelids Combined with Meibomian Gland Expression to Treat Meibomian Gland Dysfunction. Photomed Laser Surg. 2018 Jun;36(6):326-332. doi: 10.1089/pho.2017.4402. Epub 2018 Apr 24.
Results Reference
result

Learn more about this trial

Analysis of the Results of Intense Pulsed Light Treatment Previously to Laser Refractive Surgery

We'll reach out to this number within 24 hrs